H-RAS gene expression in human multinodular goiter

Histology and Histopathology

Volumn 22, Issue 4-6, 2007, Pages 409-416

  Golbert, L ^a   Kolling, J H G ^a   Leitao A H ^a   Martins, L ^b   Kimura, E T ^b   Maia, Ana Luiza ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Gene expression; H RAS; Human; Multinodular goiter; Thyrotoxicosis

Indexed keywords

COMPLEMENTARY DNA; GUANINE NUCLEOTIDE BINDING PROTEIN; H RAS PROTEIN; MESSENGER RNA; THYROGLOBULIN; THYROTROPIN; UNCLASSIFIED DRUG; PROTEIN P21;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NODULAR GOITER; ONCOGENE H RAS; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID NODULE; THYROID SURGERY; THYROTOXICOSIS; THYROTROPIN BLOOD LEVEL; TISSUE LEVEL; TOXIC GOITER; GENETICS; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE; ONCOGENE RAS; PATHOLOGY; RETROSPECTIVE STUDY;

ADULT; AGED; CELL PROLIFERATION; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION; GENES, RAS; GOITER, NODULAR; HUMANS; MALE; MIDDLE AGED; ONCOGENE PROTEIN P21(RAS); RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THYROGLOBULIN; THYROTOXICOSIS; THYROTROPIN;

EID: 33947539970     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Adjei A.A. (2001). Blocking oncogenic Ras signaling for cancer therapy. J. Natl. Cancer. Inst. 93 1062-1074.
2. Aeschimann S., Kopp P.A., Kimura E.T., Zbaeren J., Tobler A., Fey M.F. and Studer H. (1993). Morphological and functional polymorphism within clonal thyroid nodules. J. Clin. Endocrinol. Metab. 77, 846-851.
3. Barbacid M. (1987). Ras genes. Annu. Rev. Biochem. 56, 779-827.
4. Bartolone L., Vermiglio F., Finocchiaro M.D., Violi M.A., French D., Pontecorvi A., Trimarchi F. and Benvenga S. (1998). Thyroid follicular oncogenesis in iodine-deficient and iodine-sufficient areas: search for alterations of the ras, met and bFGF oncogenes and of the Rb anti-oncogene. J Endocrinol. Invest. 21, 680-687.
5. Cheng G., Lewis A.E. and Meinkoth J.L. (2003). Ras stimulates aberrant cell cycle progression and apoptosis in rat thyroid cells. Mol. Endocrinol. 17, 450-459.
6. Derwahl M. and Studer H. (2000). Multinodular goitre: much more to it than simply iodine deficiency. Baillieres Best Pract. Res. Clin. Endocrinol. Metab. 14, 577-600.
7. Derwahl M. and Studer H. (2001). Nodular goiter and goiter nodules: Where iodine deficiency falls short of explaining the facts. Exp. Clin. Endocrinol. Diabetes 109, 250-260.
8. Fagin J.A. (1998). Molecular pathogenesis of tumors of thyroid follicular cell. In: Thyroid cancer. Fagin J.A (eds). Kluwer Academic Publishers. Norwell, Massachusetts. pp 59-83.
9. Fusco A., Berlingieri M.T., Di Fiore P.P., Portella G., Grieco M. and Vecchio G. (1987). One- and two-step transformations of rat thyroid epithelial cells by retroviral oncogenes. Mol. Cell. Biol. 7, 3365-3370.
10. Garcia-Rostan G., Zhao H., Camp R.L., Pollan M., Herrero A., Pardo J., Wu R., Carcangiu M.L., Costa J. and Tallini G. (2003). Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J. Clin. Oncol. 21, 3226-3235.
11. Gerard A.C., Xhenseval V., Colin I.M., Many M.C. and Denef J.F. (2000). Evidence for co-ordinated changes between vascular endothelial growth factor and nitric oxide synthase III immunoreactivity, the functional status of the thyroid follicles, and the microvascular bed during chronic stimulation by low iodine and propylthiouracyl in old mice. Eur. J. Endocrinol. 142, 651-660.
12. Gerard A.C., Many M.C., Daumerie C., Costagliola S., Miot F., DeVijlder J.J., Colin I.M. and Denef J.F. (2002). Structural changes in the angiofollicular units between active and hypofunctioning follicles align with differences in the epithelial expression of newly discovered proteins involved in iodine transport and organification. J. Clin. Endocrinol. Metab. 87, 1291-1299.
13. Gire V. and Wynford-Thomas D. (2000). RAS oncogene activation induces proliferation in normal human thyroid epithelial cells without loss of differentiation. Oncogene 19, 737-744.
14. Gougopoulou D.M., Kiaris H., Ergazaki M., Anagnostopoulos N.I., Grigoraki V. and Spandidos D.A. (1996). Mutations and expression of the ras family genes in leukemias. Stem Cells 14, 725-729.
15. Hedinger C.E., Williams E.D. and Sobin L.H. (1988). Histological typing of thyroid tumors. In: WHO International Histological Classification of Tumours. 2nd edition. Springer-Verlag. Berlin. pp 5-6.
16. Hongyo T., Buzard G.S., Calvert R.J. and Weghorst C.M. (1993). Cold SSCP: a simple, rapid and non-radioactive method for optimized single-strand conformation polymorphism analyses. Nucleic Acid. Res. 21, 3637-3642.
17. Karga H., Lee J.K., Vickery A.L. Jr. Thor A., Gaz R.D. and Jameson J.L. (1991). Ras oncogene mutations in benign and malignant thyroid neoplasms. J. Clin. Endocrinol. Metab. 73, 832-836.
18. Kiaris H., Spandidos D.A., Jones A.S., Vaughan E.D. and Field J.K. (1995). Mutations, expression and genomic instability of the H-ras proto-oncogene in squamous cell carcinomas of the head and neck. Br. J. Cancer 72, 123-128.
19. Kimura E.T., Kopp P., Zbaeren J., Asmis L.M., Ruchti C., Maciel R.M. and Studer H. (1999). Expression of transforming growth factor beta1, beta2, and beta3 in multinodular goiters and differentiated thyroid carcinomas: a comparative study. Thyroid 9, 119-125.
20. Krohn K. and Paschke R. (2001). Clinical review 133: Progress in understanding the etiology of thyroid autonomy. J. Clin. Endocrinol. Metab. 86, 3336-3345.
21. Krohn K. and Paschke R. (2004). BRAF mutations are not an alternative explanation for the molecular etiology of ras-mutation negative cold thyroid nodules. Thyroid 14, 359-361.
22. Krohn K., Fuhrer D., Bayer Y., Eszlinger M., Brauer V., Neumann S. and Paschke R. (2005). Molecular pathogenesis of euthyroid and toxic multinodular goiter. Endocr. Rev. 26, 504-524.
23. Kupperman E., Wen W. and Meinkoth J.L. (1993). Inhibition of thyrotropin-stimulated DNA synthesis by microinjection of inhibitors of cellular Ras and cyclic AMP-dependent protein kinase. Mol. Cell Biol. 13, 4477-4484.
24. Lemoine N.R., Mayall E.S., Wyllie F.S., Williams E.D., Goyns M., Stringer B. and Wynford-Thomas D. (1989). High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 4, 159-164.
25. Liu R.T., Hou C.Y., You H.L., Huang C.C., Hock L., Chou F.F., Wang P.W. and Cheng J.T. (2004). Selective occurrence of ras mutations in benign and malignant thyroid follicular neoplasms in Taiwan. Thyroid 14, 616-621.
26. Miyakis S., Sourvinos G. and Spandidos D.A. (1998). Differential expression and mutation of the ras family genes in human breast cancer. Biochem. Biophys. Res. Commun. 251, 609-612.
27. Namba H., Rubin S.A. and Fagin J.A. (1990). Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol. Endocrinol. 4, 1474-1479.
28. Nikiforova M.N., Lynch R.A., Biddinger P.W., Alexander E.K., Dorn G.W. 2nd, Tallini G., Kroll T.G. and Nikiforov Y.E. (2003). RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J. Clin. Endocrinol. Metab. 88, 2318-2326.
29. Rivas M. and Santisteban P. (2003). TSH-activated signaling pathways in thyroid tumorigenesis. Mol. Cell. Endocrinol. 213, 31-45.
30. Spandidos D.A. and Wilkie N.M. (1984). Malignant transformation of early passage rodent cells by a single mutated human oncogene. Nature 310, 469-475.
31. Suarez H.G. (1998). Genetic alterations in human epithelial thyroid tumours. Clin. Endocrinol. 48, 531-546.
32. Suarez H.G., du Villard J.A., Severino M., Caillou B., Schlumberger M, Tubiana M., Parmentier C. and Monier R. (1990). Presence of mutations in all three ras genes in human thyroid tumors. Oncogene 5, 565-570.
33. Vasko V., Ferrand M., Di Cristofaro J., Carayon P., Henry J.F. and de Micco C. (2003). Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J. Clin. Endocrinol. Metab. 88, 2745-2752.
34. Wynford-Thomas D. (1997) Origin and progression of thyroid epithelial tumours: cellular and molecular mechanisms. Horm. Res. 47, 145-157.
35. Zachos G. and Spandidos D.A. (1997). Expression of ras protooncogenes: regulation and implications in the development of human tumors. Crit. Rev. Oncol. Hematol. 26, 65-75.